Crystals of quinazoline derivative and preparation method therefor

US10689359B2 · kind B2 · utility

Assignee

• XUANZHU PHARMA CO., LTD. · CN

Inventors

• Chutian Shu · Jinan, CN
• Jinyuan Wang · Beijing, CN
• Zhenhua Wang · Kawasaki, JP
• Yuzhen Feng · Jinan, CN

Key dates

• Filing date: Dec 23, 2016
• Grant date: Jun 23, 2020
• Expiry date: Dec 27, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to Crystal form I, Crystal form II and Crystal form III of N-(4-((3-chloro-4-fluorophenyl)amino)-7-((7-methyl-7-azaspiro[3.5]nonan-2-yl)methoxy)quinazolin-6-yl)acrylamide represented by the following Formula (I), and preparation methods thereof, wherein the Crystal form I has an X-ray powder diffraction pattern having characteristic peaks at the 2θ positions of 6.7±0.2°, 7.9±0.2°, 8.6±0.2°, 12.0±0.2°, 13.9±0.2°, 15.9±0.2°, 17.3±0.2°, 18.3±0.2°, 18.7±0.2°, 21.0±0.2°, and 23.0±0.2°, as determined by using Cu-Kα radiation; the Crystal form II has an X-ray powder diffraction pattern having characteristic peaks at the 2θ positions of 6.9±0.2°, 8.5±0.2°, 14.8±0.2°, 15.6±0.2°, 16.7±0.2°, 17.1±0.2°, 17.9±0.2°, 18.7±0.2°, 19.1±0.2°, 21.5±0.2°, 23.5±0.2°, and 25.7±0.2°, as determined by using Cu-Kα radiation; and the Crystal form III has an X-ray powder diffraction pattern having characteristic peaks at the 2θ positions of 4.9±0.2°, 6.1±0.2°, 7.4±0.2°, 11.4±0.2°, 12.2±0.2°, 16.6±0.2°, and 18.4±0.2°, as determined by using Cu-Kα radiation.